Literature DB >> 27476442

Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy.

Fanfei Meng1,2, Ning Han1,3, Yoon Yeo1,4.   

Abstract

INTRODUCTION: Chemotherapeutic drugs are used in combination to target multiple mechanisms involved in cancer cell survival and proliferation. Carriers are developed to deliver drug combinations to common target tissues in optimal ratios and desirable sequences. Nanoparticles (NP) have been a popular choice for this purpose due to their ability to increase the circulation half-life and tumor accumulation of a drug. Areas covered: We review organic NP carriers based on polymers, proteins, peptides, and lipids for simultaneous delivery of multiple anticancer drugs, drug/sensitizer combinations, drug/photodynamic therapy or drug/photothermal therapy combinations, and drug/gene therapeutics with examples in the past three years. Sequential delivery of drug combinations, based on either sequential administration or built-in release control, is introduced with an emphasis on the mechanistic understanding of such control. Expert opinion: Recent studies demonstrate how a drug carrier can contribute to co-localizing drug combinations in optimal ratios and dosing sequences to maximize the synergistic effects. We identify several areas for improvement in future research, including the choice of drug combinations, circulation stability of carriers, spatiotemporal control of drug release, and the evaluation and clinical translation of combination delivery.

Entities:  

Keywords:  Multimodal chemotherapy; drug synergism; nanoparticles; ratiometric delivery; sequential delivery; simultaneous delivery; spatiotemporal control

Mesh:

Substances:

Year:  2016        PMID: 27476442      PMCID: PMC5385259          DOI: 10.1080/17425247.2016.1218464

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  137 in total

1.  Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer.

Authors:  Ilkoo Noh; Hyun-Ouk Kim; Jihye Choi; Yuna Choi; Dong Ki Lee; Yong-Min Huh; Seungjoo Haam
Journal:  Biomaterials       Date:  2015-03-30       Impact factor: 12.479

2.  Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

Authors:  Xi-Chun Hu; Jian Zhang; Bing-He Xu; Li Cai; Joseph Ragaz; Zhong-Hua Wang; Bi-Yun Wang; Yue-E Teng; Zhong-Sheng Tong; Yue-Yin Pan; Yong-Mei Yin; Chang-Ping Wu; Ze-Fei Jiang; Xiao-Jia Wang; Gu-Yin Lou; Dong-Geng Liu; Ji-Feng Feng; Jian-Feng Luo; Kang Sun; Ya-Jia Gu; Jiong Wu; Zhi-Min Shao
Journal:  Lancet Oncol       Date:  2015-03-18       Impact factor: 41.316

3.  Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.

Authors:  Elfriede R Greimel; Vesna Bjelic-Radisic; Jacobus Pfisterer; Felix Hilpert; Fedor Daghofer; Andreas du Bois
Journal:  J Clin Oncol       Date:  2006-02-01       Impact factor: 44.544

4.  Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.

Authors:  Xiao Zhao; Feng Li; Yiye Li; Hai Wang; He Ren; Jing Chen; Guangjun Nie; Jihui Hao
Journal:  Biomaterials       Date:  2015-01-15       Impact factor: 12.479

5.  Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy:a multicenter phase III study.

Authors:  V Lorusso; F Giotta; R Bordonaro; E Maiello; S Del Prete; V Gebbia; G Filippelli; S Pisconti; S Cinieri; S Romito; F Riccardi; R Forcignanò; M Ciccarese; L Petrucelli; V Saracino; L I Lupo; A Gambino; S Leo; G Colucci
Journal:  Int J Oncol       Date:  2014-08-18       Impact factor: 5.650

6.  Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.

Authors:  Elizabeth R Plimack; Jean H Hoffman-Censits; Rosalia Viterbo; Edouard J Trabulsi; Eric A Ross; Richard E Greenberg; David Y T Chen; Costas D Lallas; Yu-Ning Wong; Jianqing Lin; Alexander Kutikov; Efrat Dotan; Timothy A Brennan; Norma Palma; Essel Dulaimi; Reza Mehrazin; Stephen A Boorjian; William Kevin Kelly; Robert G Uzzo; Gary R Hudes
Journal:  J Clin Oncol       Date:  2014-05-12       Impact factor: 44.544

7.  Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.

Authors:  Anupama Mittal; Deepak Chitkara; Stephan W Behrman; Ram I Mahato
Journal:  Biomaterials       Date:  2014-05-14       Impact factor: 12.479

8.  Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

Authors:  Michael J Lee; Albert S Ye; Alexandra K Gardino; Anne Margriet Heijink; Peter K Sorger; Gavin MacBeath; Michael B Yaffe
Journal:  Cell       Date:  2012-05-11       Impact factor: 41.582

Review 9.  Natural and synthetic polymers as inhibitors of drug efflux pumps.

Authors:  Martin Werle
Journal:  Pharm Res       Date:  2007-09-26       Impact factor: 4.200

10.  Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine.

Authors:  Takayo Fukuda; Masahiko Tanabe; Kokoro Kobayashi; Ippei Fukada; Shunji Takahashi; Takuji Iwase; Yoshinori Ito
Journal:  Springerplus       Date:  2015-07-26
View more
  5 in total

1.  Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic Outcome in Pancreatic Cancer.

Authors:  Mubin Tarannum; Md Akram Hossain; Bryce Holmes; Shan Yan; Pinku Mukherjee; Juan L Vivero-Escoto
Journal:  Small       Date:  2021-11-10       Impact factor: 13.281

2.  Camouflaging Nanoparticles for Ratiometric Delivery of Therapeutic Combinations.

Authors:  Fanfei Meng; Jianping Wang; Qineng Ping; Yoon Yeo
Journal:  Nano Lett       Date:  2019-02-07       Impact factor: 11.189

Review 3.  Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review).

Authors:  Wararat Chiangjong; Somchai Chutipongtanate; Suradej Hongeng
Journal:  Int J Oncol       Date:  2020-07-10       Impact factor: 5.650

Review 4.  Polymer nanoparticle-assisted chemotherapy of pancreatic cancer.

Authors:  Tianqi Su; Bo Yang; Tianren Gao; Tongjun Liu; Jiannan Li
Journal:  Ther Adv Med Oncol       Date:  2020-05-08       Impact factor: 8.168

Review 5.  Bioresponsive Nanomaterials: Recent Advances in Cancer Multimodal Imaging and Imaging-Guided Therapy.

Authors:  Zeng Zeng; Huali Gao; CongXian Chen; Lianbo Xiao; Kun Zhang
Journal:  Front Chem       Date:  2022-03-18       Impact factor: 5.221

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.